Articles

Tivdak (tisotumab vedotin-tftv), an antibody drug conjugate, was granted accelerated approval by the FDA in September 2021 for patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

sBLA for Tivdak Granted FDA Priority Review for Recurrent, Metastatic Cervical Cancer 

Rinatabart sesutecan (Rina-S; PRO1184) showed encouraging antitumor activity and tolerability in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

FDA Fast Tracks ProfoundBio’s Novel Ovarian Cancer Treatment

Analysis reveals how QbTest is used to measure the effectiveness of ADHD drugs. 

Monitoring Response to Attention-Deficit Hyperactivity Disorder Medication 

Scemblix (asciminib) was approved by the FDA in October 2021 for patients with chronic phase chronic myeloid leukemia previously administered two or more tyrosine kinase inhibitors and for adults with chronic phase chronic myeloid leukemia with the T315I mutation.

Chronic Myeloid Leukemia Treatment Combo Shows Promise in Phase III Trial

In the midst of being approved for commercial manufacturing of Pluvict, the 70,000 square-foot site was built specifically to accommodate RLT production. 

Novartis Opens New Radioligand Therapy Manufacturing Facility in Indianapolis

Trials will evaluate four novel agents for cancers that include essential thrombocythemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-small cell lung cancer, endometrial carcinoma, and metastatic castration-resistant prostate cancer.

Merck Highlights Robust Oncology, Hematology Pipeline With Four Agents in Phase III Trials

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

CVS Announces Formulary Changes to Facilitate Adoption of Humira Biosimilars

LillyDirect will facilitate access to medications by connecting patients with independent telehealth providers, bypassing the need to obtain a prescription from a physician and then going to a pharmacy to fill it.

Eli Lilly Announces New Telehealth, Home Delivery Option for Popular Weight Loss Drug

Cretostimogene grenadenorepvec is a novel, intravesically delivered oncolytic immunotherapy under evaluation for the treatment of patients with high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without Ta or T1 tumors.

Novel Treatment for Non–Muscle Invasive Bladder Cancer Granted FDA Fast Track, Breakthrough Therapy Designation 

Electronic health record messaging network found to improve communication and lead to better medication adherence.   

News